Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 6.09% over the past year to ($1.08), which beat the estimate of ($1.09).

Revenue of $13,299,000 rose by 22829.31% year over year, which beat the estimate of $10,980,000.

Guidance

Revance Therapeutics Sees FY21 Non-GAAP Operating Expenses $270M-$285M; Sees Non-GAAP R&D Expenses $95M-$105M

Conference Call Details

Date: May 10, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/mkn6fb8e

Recent Stock Performance

Company's 52-week high was at $34.62

Company's 52-week low was at $18.39

Price action over last quarter: Up 5.87%

Company Profile